DMAC Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of -255.85%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 88.34%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that DiaMedica Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe DiaMedica Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Palatin Technologies's return on equity of --.

DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 88.34%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than DiaMedica Therapeutics, Inc..

DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

DiaMedica Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is higher than Palatin Technologies's net income of --. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 88.34%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than DiaMedica Therapeutics, Inc..

DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of 52.48%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat XOMA Royalty Corp.'s return on equity of 17.31%.

DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 88.34%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 147.51%. Given that XOMA Royalty Corp. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than DiaMedica Therapeutics, Inc..

DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 9.06x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.